Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...

Novo Nordisk extended a four-day winning streak on Friday, adding 5.18 percent to close at $88.08 apiece as investors cheered ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

GLP-1 drugs like Wegovy and Ozempic, which are made by Novo Nordisk (NVO), have seen a shortage since 2022 amid rising demand. While that shortage was in effect, it allowed compounders - drug makers ...

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

Stocks are lower, with the Dow down over 300 points, as investors unpack weak consumer sentiment data and the UNH investigation ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...

Novo Nordisk (NYSE: NVO) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli ...

European stocks rose for a ninth straight week, boosted by shares of chemicals companies and Novo Nordisk A/S gains. Traders are also looking ahead to German elections on Sunday.

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...